查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403520

2030 年白蛋白市場預測：按產品類型、應用、最終用戶和地區分類的全球分析

Albumin Market Forecasts to 2030 - Global Analysis By Product Type (Bovine Serum Albumin, Human Serum Albumin and Recombinant Albumin), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球白蛋白市場規模將達到 65 億美元，預計到 2030 年將達到 103 億美元，預測期內複合年成長率為 6.7%。

白蛋白是肝臟產生的必需蛋白質，存在於血漿中。它對於人體發生的許多生理過程至關重要。作為載體蛋白，白蛋白在循環中輸送多種物質，包括維生素、脂肪酸、荷爾蒙和藥物。

根據美國癌症協會的2023年癌症統計數據，預計2023年美國將通報約193萬名癌症病例。癌症的高負擔預計將增加對 HSA 的需求，從而推動該行業在預測期內的成長。

人口高齡化加劇

隨著年齡的成長，人們越來越容易受到各種健康問題的影響，包括慢性病、肝病和需要藥物治療的疾病。低白蛋白血症（一種以血液白蛋白水平低為特徵的疾病）在老年人中很常見。因此，對基於白蛋白的治療和治療來解決各種醫學疾病的需求不斷增加。因此，高齡化導致醫療保健成本上升，使得基於白蛋白的治療方法等先進醫療方法更容易獲得，並推動市場擴張。

替代產品和替代品的可得性

白蛋白市場的價格壓力可能源自於公司保持競爭力所需的替代品的可用性。因此，我們的白蛋白產品可能會降低報酬率或降低價格，進而影響我們的收益來源。如果白蛋白被接受並且顯示出同樣有效，醫療保健專業人員和患者可以選擇使用替代品或替代品來代替白蛋白。對白蛋白治療的需求減少可能會影響銷售和市場擴張並阻礙市場成長。

生物製藥產業的擴張

添加白蛋白可提高藥物溶解度、穩定性和生物利用度。白蛋白透過穩定蛋白質並作為藥物輸送系統來提高生物製藥的功效。由於白蛋白具有生物相容性並且能夠封裝藥物，因此它經常用於開發創新的藥物輸送系統，例如基於奈米顆粒的藥物輸送系統。人們對生物製藥研究和開發的興趣日益濃厚，導致白蛋白供應商和製藥公司之間建立聯盟和夥伴關係，推動創新和市場擴張。

製造成本高

精打細算的醫院、醫療保健系統和醫療服務提供者可能會猶豫是否要花錢購買昂貴的白蛋白產品。由於生產成本較高，生產白蛋白的製藥公司和製造商的報酬率可能較低。我們資助研發和創新以推進基於白蛋白的療法的能力可能會受到影響，從而抑制市場。

COVID-19 的影響

為了治療 COVID-19重症患者，在大流行初期，對重症患者監護藥物（尤其是白蛋白）的需求增加。在某些情況下，白蛋白被用來補充損失量並為嚴重患者提供支持性護理。由於與疫情相關的資源重新分配以及對非必要研究活動的限制，一些與白蛋白及其可能用途相關的臨床研究和研究計劃可能被推遲或中斷。

牛血清白蛋白細分市場預計在預測期內規模最大

由於研究、診斷和生物技術行業的高需求，預計牛血清白蛋白細分市場將出現良好的成長。牛血清白蛋白市場服務於各種企業並服務於相對不同的目的。牛血清白蛋白用於生物製藥和生物技術領域，並用於製造某些疫苗、醫療設備和生物製藥，推動市場成長。

診斷領域預計在預測期內複合年成長率最高

這是因為許多臨床測試和測定都會量化白蛋白（一種重要的生物標記），以評估健康和疾病狀態。作為完整代謝組的一部分，經常透過肝功能測試和血液檢查來評估血清白蛋白水平。非典型白蛋白水平可能表示營養不良、肝臟或腎臟損傷或其他醫療狀況。除了定期驗血外，白蛋白水平的變化還可用作診斷某些醫療問題的標誌。因此，低白蛋白血症（血清白蛋白水平降低）可能預示著許多疾病，包括肝臟疾病、腎臟疾病、營養不良和發炎疾病。

比最大的地區

北美在預測期內佔據最大的市場佔有率，因為現代化的醫療設施、長期的醫療基礎設施、高醫療保健支出等因素預計將導致該地區在全球白蛋白產業中佔據重要的市場地位。此外，北美白蛋白市場受到加拿大衛生署和美國食品藥物管理局（FDA）等衛生當局嚴格的法律規範的監管。遵守監管要求對於產品核可和市場准入至關重要，從而推動市場成長。

複合年成長率最高的地區：

由於醫療領域和白蛋白，特別是人類血清白蛋白（HSA）用於各種治療目的的頻繁使用，預計亞太地區在預測期內將表現出最高的複合年成長率。當地醫療系統使用白蛋白來治療損傷、肝臟疾病、嚴重監護、手術和其他疾病。此外，亞太地區的生物製藥產業正在顯著成長。中國和印度正在成為生物技術和製藥行業的主要參與者，支持白蛋白產品的生產和銷售。

主要進展：

Aspira 於 2023 年 12 月推出，憑藉在戶外休閒領域 30 多年的專業知識和行業洞察力，繼續支持和管理領先的戶外休閒活動線上市場 ReserveAmerica®。

2023 年 11 月，美國高品質血漿採集領域的領導者、凱瑞恩生物製藥公司 KEDPLASMA 宣布了一個新項目，旨在改善捐贈者體驗並提高採集中心的卓越標準。我們很自豪地宣布進行全面整修。

2023 年 11 月，Aspira (TM) 宣布收購了 Astra 和 Campground Manager 軟體平台供應商 Mission Management。

提供免費客製化

訂閱此報告的客戶將收到以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球白蛋白市場：依產品類型

  • 牛血清白蛋白
  • 人血清白蛋白
  • 重組白蛋白

第6章全球白蛋白市場：依應用分類

  • 藥物輸送
  • 疫苗
  • 診斷
  • 體外受精
  • 醫療設備塗層
  • 介質和穩定劑
  • 其他用途

第7章 全球白蛋白市場：依最終使用者分類

  • 研究機構
  • 製藥和生物技術公司
  • 醫院
  • 其他最終用戶

第8章全球白蛋白市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Kedrion SpA
  • Lazuline Bio
  • Albumin Bioscience
  • Aspira Chemical
  • ALBUMEDIX
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Cyagen Biosciences
  • CSL Behring（CSL）
  • Takeda Pharmaceutical Company Limited
  • InVitria
  • Grifols, SA
  • Biorbyt Ltd.
  • Octapharma AG
  • Akron Biotech
  • Novozymes AS
  • China Biologic Products Holdings Inc.
  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • Medxbio Pte Ltd
Product Code: SMRC24745

According to Stratistics MRC, the Global Albumin Market is accounted for $6.5 billion in 2023 and is expected to reach $10.3 billion by 2030 growing at a CAGR of 6.7% during the forecast period. A necessary protein produced by the liver, albumin is present in blood plasma. It is essential to many physiological processes that occur in the human body. As a carrier protein, albumin moves different materials throughout the circulation, including vitamins, fatty acids, hormones, and medications.

According to the American Cancer Society 2023 Cancer Statistics, about 1.93 million cancer cases are estimated to be reported in 2023 in the United States. The high burden of cancer is expected to augment the demand for HSA, thereby boosting segment growth over the forecast period.

Market Dynamics:

Driver:

Growing aging population

People are increasingly vulnerable as they become older to a variety of health problems, including chronic diseases, liver disease, and ailments that need to be treated with medicine. Among elderly persons, hypoalbuminemia a disorder marked by low blood levels of albumin is common. As a result, there is an increased need for therapies and treatments based on albumin to address various medical disorders. Thus the aging population is linked to rising healthcare costs, which in turn makes sophisticated medical treatments like albumin-based therapies more accessible, which fuels market expansion.

Restraint:

Availability of substitute products and alternatives

Price pressure in the albumin market might result from the availability of substitute goods, as businesses aim to maintain their competitiveness. This may lead to lower profit margins or price reductions for goods based on albumin, which would impact revenue streams. Healthcare professionals and patients may choose to use replacement goods or alternatives in place of albumin if they are accepted and show equivalent efficacy. Sales and market expansion may be impacted by this decline in the demand for albumin-based treatments thus hampering the growth of the market.

Opportunity:

Expanding biopharmaceutical industry

Pharmaceutical goods are formulated with albumin to increase the medications' solubility, stability, and bioavailability. It improves the effectiveness of biopharmaceuticals by stabilizing proteins and serving as a medication delivery system. Because albumin is biocompatible and can encapsulate medications, it is frequently used in the development of innovative drug delivery systems, such as those based on nanoparticles. Growing interest in biopharmaceutical R&D leads to alliances and partnerships between albumin suppliers and pharmaceutical firms, which promotes innovation and market expansion.

Threat:

High cost of production

Budget-conscious hospitals, healthcare systems, and providers could be hesitant to spend money on pricey albumin products, which would restrict utilization or make people, choose less costly options. Due to the high manufacturing costs, pharmaceutical businesses or manufacturers who produce albumin may see a decrease in their profit margins. Their capacity to fund R&D and innovation to advance albumin-based therapy may be impacted by this thereby impeding the market.

COVID-19 Impact

In order to treat severe COVID-19 patients, there was an increase in demand for critical care treatments during the early stages of the pandemic, particularly albumin. In several instances, albumin was utilized to replenish lost volume and provide supportive care for patients in severe condition. The pandemic-related resource reallocation and limitations on non-essential research activities may have caused several clinical studies and research projects pertaining to albumin or its possible uses to be postponed or interrupted.

The bovine serum albumin segment is expected to be the largest during the forecast period

The bovine serum albumin segment is estimated to have a lucrative growth, due to larger demands of the research, diagnostics, and biotechnology industries, human serum albumin (HSA) is predominantly employed for therapeutic purposes in the healthcare industry. The marketplaces for bovine serum albumin serve various businesses and serve relatively different goals. The biopharmaceutical and biotechnology sectors both use bovine serum albumin and it is employed in the creation and manufacturing of specific vaccinations, medical devices, and biologic medications thus encouraging the growth of the market.

The diagnostics segment is expected to have the highest CAGR during the forecast period

The diagnostics segment is anticipated to witness the highest CAGR growth during the forecast period, because in order to evaluate health and disease states, a number of clinical tests and assays quantify albumin, a critical biomarker. Serum albumin levels are frequently assessed in blood tests as part of liver function tests or full metabolic panels. Atypical albumin levels may suggest malnourishment, disorders of the liver or kidneys, or other medical conditions. Changes in albumin levels can be used as markers to diagnose certain medical problems in addition to regular blood testing. Thus hypoalbuminemia, or low serum albumin levels, can indicate a number of illnesses, including liver disease, renal problems, malnourishment, and inflammatory diseases.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the North America's modern medical facilities, long-standing healthcare infrastructure, and high healthcare spending all contribute to the region's significant market position in the worldwide albumin industry. Additionally, strict regulatory frameworks set by health agencies like Health Canada and the U.S. Food and Drug Administration (FDA) govern the albumin market in North America. Adherence to regulatory requirements is crucial for both product approvals and market access boosts the growth of the market.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the medical field, albumin particularly human serum albumin (HSA) that is frequently utilized for a range of therapeutic purposes. Albumin is used by the medical systems in the area to treat injuries, liver illnesses, critical care, operations, and other ailments. Moreover, the biopharmaceutical sector has grown significantly in the Asia Pacific area. China and India are becoming as major actors in the biotechnology and pharmaceutical industries, helping to produce and market goods based on albumin.

Key players in the market:

Some of the key players profiled in the Albumin Market include Kedrion S.p.A., Lazuline Bio, Albumin Bioscience, Aspira Chemical, ALBUMEDIX, Merck KGaA, Thermo Fisher Scientific Inc., Cyagen Biosciences, CSL Behring (CSL), Takeda Pharmaceutical Company Limited, InVitria, Grifols, S.A., Biorbyt Ltd., Octapharma AG, Akron Biotech, Novozymes AS, China Biologic Products Holdings Inc., Baxter International Inc., Bristol-Myers Squibb Company and Medxbio Pte Ltd

Key Developments:

In December 2023, Aspira Launches with More Than 30 Years of Expertise and Industry Insight in the Outdoor Recreation Space and the company will continue to support and manage ReserveAmerica®, the renowned online marketplace for outdoor recreation activities

In November 2023, KEDPLASMA, a Kedrion Biopharma company and a leader in the US in the collection of high-quality plasma, is proud to announce a comprehensive remodeling initiative aimed at enhancing the experience of its donors and raising the standard of excellence in its collection centers.

In November 2023, Aspira™ announced that it has acquired Mission Management, provider of the Astra and Campground Manager software platforms.

Product Types Covered:

  • Bovine Serum Albumin
  • Human Serum Albumin
  • Recombinant Albumin

Applications Covered:

  • Drug Delivery
  • Vaccines
  • Diagnostics
  • In Vitro Fertilization
  • Medical Device Coating
  • Culture Medium & Stabilizer
  • Other Applications

End Users Covered:

  • Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Albumin Market, By Product Type

  • 5.1 Introduction
  • 5.2 Bovine Serum Albumin
  • 5.3 Human Serum Albumin
  • 5.4 Recombinant Albumin

6 Global Albumin Market, By Application

  • 6.1 Introduction
  • 6.2 Drug Delivery
  • 6.3 Vaccines
  • 6.4 Diagnostics
  • 6.5 In Vitro Fertilization
  • 6.6 Medical Device Coating
  • 6.7 Culture Medium & Stabilizer
  • 6.8 Other Applications

7 Global Albumin Market, By End User

  • 7.1 Introduction
  • 7.2 Research Institutes
  • 7.3 Pharmaceutical & Biotechnology Companies
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Albumin Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Kedrion S.p.A.
  • 10.2 Lazuline Bio
  • 10.3 Albumin Bioscience
  • 10.4 Aspira Chemical
  • 10.5 ALBUMEDIX
  • 10.6 Merck KGaA
  • 10.7 Thermo Fisher Scientific Inc.
  • 10.8 Cyagen Biosciences
  • 10.9 CSL Behring (CSL)
  • 10.10 Takeda Pharmaceutical Company Limited
  • 10.11 InVitria
  • 10.12 Grifols, S.A.
  • 10.13 Biorbyt Ltd.
  • 10.14 Octapharma AG
  • 10.15 Akron Biotech
  • 10.16 Novozymes AS
  • 10.17 China Biologic Products Holdings Inc.
  • 10.18 Baxter International Inc.
  • 10.19 Bristol-Myers Squibb Company
  • 10.20 Medxbio Pte Ltd

List of Tables

  • Table 1 Global Albumin Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Albumin Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
  • Table 4 Global Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
  • Table 5 Global Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
  • Table 6 Global Albumin Market Outlook, By Application (2021-2030) ($MN)
  • Table 7 Global Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 8 Global Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 9 Global Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 10 Global Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
  • Table 11 Global Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
  • Table 12 Global Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
  • Table 13 Global Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 14 Global Albumin Market Outlook, By End User (2021-2030) ($MN)
  • Table 15 Global Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 16 Global Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 17 Global Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 18 Global Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 19 North America Albumin Market Outlook, By Country (2021-2030) ($MN)
  • Table 20 North America Albumin Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 21 North America Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
  • Table 22 North America Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
  • Table 23 North America Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
  • Table 24 North America Albumin Market Outlook, By Application (2021-2030) ($MN)
  • Table 25 North America Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 26 North America Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 27 North America Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 28 North America Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
  • Table 29 North America Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
  • Table 30 North America Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
  • Table 31 North America Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 32 North America Albumin Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 North America Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 34 North America Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 35 North America Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 36 North America Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 37 Europe Albumin Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Europe Albumin Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 39 Europe Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
  • Table 40 Europe Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
  • Table 41 Europe Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
  • Table 42 Europe Albumin Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 Europe Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 44 Europe Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 45 Europe Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 46 Europe Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
  • Table 47 Europe Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
  • Table 48 Europe Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
  • Table 49 Europe Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 50 Europe Albumin Market Outlook, By End User (2021-2030) ($MN)
  • Table 51 Europe Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 52 Europe Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 53 Europe Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 54 Europe Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 55 Asia Pacific Albumin Market Outlook, By Country (2021-2030) ($MN)
  • Table 56 Asia Pacific Albumin Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 57 Asia Pacific Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
  • Table 58 Asia Pacific Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
  • Table 59 Asia Pacific Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
  • Table 60 Asia Pacific Albumin Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Asia Pacific Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 62 Asia Pacific Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 63 Asia Pacific Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 64 Asia Pacific Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
  • Table 65 Asia Pacific Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
  • Table 66 Asia Pacific Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
  • Table 67 Asia Pacific Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 68 Asia Pacific Albumin Market Outlook, By End User (2021-2030) ($MN)
  • Table 69 Asia Pacific Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 70 Asia Pacific Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 71 Asia Pacific Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 72 Asia Pacific Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 73 South America Albumin Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 South America Albumin Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 75 South America Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
  • Table 76 South America Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
  • Table 77 South America Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
  • Table 78 South America Albumin Market Outlook, By Application (2021-2030) ($MN)
  • Table 79 South America Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 80 South America Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 81 South America Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 82 South America Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
  • Table 83 South America Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
  • Table 84 South America Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
  • Table 85 South America Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 86 South America Albumin Market Outlook, By End User (2021-2030) ($MN)
  • Table 87 South America Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 88 South America Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 89 South America Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 90 South America Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 91 Middle East & Africa Albumin Market Outlook, By Country (2021-2030) ($MN)
  • Table 92 Middle East & Africa Albumin Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 93 Middle East & Africa Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
  • Table 94 Middle East & Africa Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
  • Table 95 Middle East & Africa Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
  • Table 96 Middle East & Africa Albumin Market Outlook, By Application (2021-2030) ($MN)
  • Table 97 Middle East & Africa Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 98 Middle East & Africa Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 99 Middle East & Africa Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 100 Middle East & Africa Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
  • Table 101 Middle East & Africa Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
  • Table 102 Middle East & Africa Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
  • Table 103 Middle East & Africa Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 104 Middle East & Africa Albumin Market Outlook, By End User (2021-2030) ($MN)
  • Table 105 Middle East & Africa Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 106 Middle East & Africa Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 107 Middle East & Africa Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 108 Middle East & Africa Albumin Market Outlook, By Other End Users (2021-2030) ($MN)